Leaflet EVEROLIMUS MYLAN 10mg tablets


Indicated for: cancer; post-transplant immunosuppression

Route of administration: oral

Substance: everolimus (immunosuppressant)

ATC: L01EG02 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mammalian target of rapamycin (MTOR) kinase inhibitors)

Precautions:
Avoid grapefruit
Avoid grapefruit

Avoid grapefruit and grapefruit juice.

Avoid live vaccines
Avoid live vaccines

Avoid live vaccines during treatment if contraindicated.

Immunosuppression / infection risk
Immunosuppression / infection risk

This medicine may increase the risk of infections.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Breastfeeding warning
Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

Everolimus is a medication used in the treatment of certain types of cancer, as well as for preventing organ rejection after transplantation. It works by inhibiting a protein involved in cell growth and multiplication, thus helping to slow disease progression and reduce the risk of transplant rejection.

Everolimus is usually administered as tablets, according to the doctor's instructions, and the dose is adjusted depending on the condition being treated and the patient's response to therapy.

Side effects may include decreased immunity, infections, mouth ulcers, fatigue, digestive disorders, or increased blood sugar and cholesterol levels. In rare cases, severe reactions may occur, which is why careful monitoring is necessary during treatment.

Everolimus is an important option for patients with certain forms of cancer or who have undergone a transplant, helping to improve prognosis and increase the chances of treatment success.

General data about EVEROLIMUS MYLAN 10mg

  • Substance: everolimus
  • Date of last drug list: 01-03-2022
  • Commercial code: W68390001
  • Concentration: 10mg
  • Pharmaceutical form: tablets
  • Quantity: 30
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: SYNTHON HISPANIA SL - SPANIA
  • Holder: MYLAN PHARMACEUTICALS LIMITED - IRLANDA
  • Number: 10989/2018/01
  • Shelf life: 3 years

Pharmaceutical forms available for everolimus

Concentrations available for everolimus

  • 0.1mg
  • 0.25mg
  • 0.5mg
  • 0.75mg
  • 10mg
  • 1mg
  • 2.5mg
  • 2mg
  • 3mg
  • 5mg